Indegene Limited Reports Strong Q3 FY25 Results, Revenue Up to ₹7,204 Million

Bengaluru, India | January 30, 2025
Indegene Limited (NSE: INDGN, BSE: 544172) has announced its unaudited financial results for Q3 FY25, showing strong revenue growth and profitability. The company’s board approved its financial statements for the quarter ended December 31, 2024, alongside key strategic developments.

---

Key Financial Highlights (₹ in million)​

The company reported a 6.2% YoY growth in revenue, reaching ₹7,204 million in Q3 FY25. Net profit stood at ₹1,097 million, reflecting a 11% YoY increase, while EBITDA saw a notable rise due to improved cost efficiencies.

---

Segment-Wise Performance (₹ in million)​

Enterprise Medical Solutions emerged as the fastest-growing segment, while Omnichannel Activation saw a minor decline.

---

Corporate Announcements​

1. ESOP & RSU Allotment: The company allotted shares under its ESOP 2020 and RSU 2020 plans.
2. IPO Proceeds Utilization: Indegene successfully completed its IPO in May 2024, raising ₹7,600 million through a fresh issue.
3. UK Business Transfer: The company’s UK branch will be transferred to Indegene Healthcare UK Limited before March 31, 2025.

---

Management Commentary​

Ash Gupta, CEO & Executive Director of Indegene, stated:
"Our strong performance in Q3 FY25 reflects our continued growth momentum in the life sciences commercialization space. With investments in digital transformation, we remain confident in achieving our long-term growth objectives."

---

Strategic Outlook​

• Indegene remains bullish on the Enterprise Medical Solutions segment, expecting further revenue acceleration.
• The company is actively expanding its global footprint, particularly in Europe and the US.
• Margin expansion efforts will continue, with a focus on operational efficiencies and technology investments.

---

Conclusion​

Indegene’s Q3 FY25 results reaffirm its strong market positioning and growth trajectory. With robust revenue growth, a disciplined cost structure, and expanding global operations, the company remains a promising player in the healthcare technology and commercialization sector.